(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act: | ||||||||||||||
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
$0.001 par value per share |
EVELO BIOSCIENCES, INC. | |||||||||||
Date: June 1, 2022 | By: | /s/ Daniel S. Char | |||||||||
Daniel S. Char | |||||||||||
General Counsel & Secretary |
Cover Page |
May 31, 2022 |
---|---|
Cover [Abstract] | |
Document Type | 8-K |
Document Period End Date | May 31, 2022 |
Entity Registrant Name | EVELO BIOSCIENCES, INC. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-38473 |
Entity Tax Identification Number | 46-5594527 |
Entity Address, Address Line One | 620 Memorial Drive |
Entity Address, City or Town | Cambridge |
Entity Address, State or Province | MA |
Entity Address, Postal Zip Code | 02139 |
City Area Code | (617) |
Local Phone Number | 577-0300 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock,$0.001 par value per share |
Trading Symbol | EVLO |
Security Exchange Name | NASDAQ |
Entity Emerging Growth Company | true |
Entity Ex Transition Period | false |
Entity Central Index Key | 0001694665 |
Amendment Flag | false |
_%H,
M+@S4^:E,N &KR##3=#!039]@%[@:6Q:13")1+OE69;?UM77001_;G:-&N^4T
M6D?;J.TTJD_+[#]66Y&-*&ZK-:6@?06=E$IK21^(9B@;<4\$Q1@*8A3D&0)]
M#3HK??E73VL'E51*QJ%R8RGQ=JL2C+D)-5WZTSU8J)K&\8Z
MGEP%[#&6\BQ;_'< $BO4OP_)L3V13JENFMRW],QUS11P.8Q3!5)P<25+5_R
M?,FUW,HN+"VR>92D 0U1,PTN[C;!W^AKA;X:\+&3=I/)ZW0+'Q7 ):=,,ZA'
M/()-W=,P6,(<@]5K8MDW?<1BW=\8![H[L!W"]'7%DI#L2VJ6Y
M:Z#[UU&\NQ=7YOU35?8LRDQ 0H@3' L52 4*2 Y)&$(B AC:PO/6J;8&H8
M;S1Z&Y$]6ZBM)AYF>*@U1T:XIRM.7T[1EOJ@+ZAH!!S]2RK:TFG[HHK6<5WP
MUAT_-X].7VR>25;?F'_ZXO]02P,$% @ \SS!5%PG[NGI*%L9Z)D7B0P=XT>"BVA:@E0Y)/;[^4;"?Q(3M:2X 5P&AW2Y2J^-?79+&H
M?OO+];987&+=Y%6YMZ0[9+G TE_K+_YLW;OP'\^<^/QXM?
M*W^QQ;)='-9H6PR+J[P]6WP.V'Q9Q+K:+CY7]9?\T@+L]Q<=5N